Business
GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million
PARIS, July 01, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/4fc2fe63b49d08ae42a972d6f3bc100a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ymsX4XPPEl.Ko3sfv69uIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4fc2fe63b49d08ae42a972d6f3bc100a","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, July 01, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p"},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a private placement of EUR 3,908,715.39 subscribed by a limited number of investors (the "Private Placement").","length":432,"tagName":"p"},{"type":"text","content":""We would like to thank our existing shareholders for their continued support, as well as the new international investors who have joined us in this important financing round," commented Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "The investment reflects the market's recognition of GenSight's unique position and the significant potential of our therapeutic programs. With this funding, we remain well-positioned to execute on our strategic objectives and advance our regulatory initiatives, with the upcoming opening of the French Named Patient Access (AAC) program representing a key inflection point for the company."","length":673,"tagName":"p"},{"type":"text","content":"The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des marchés financiers – the "AMF"). However, in accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the "Prospectus Regulation&q...